# ARCHES (NCT02677896)

> A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02677896
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Metastatic Hormone Sensitive Prostate Cancer
- Interventions: Enzalutamide; Placebo
- Enrollment: 1150
- Primary outcome: Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria
- Primary outcome: rPFS Based on ICR of Bone Scan According to Protocol Assessment Criteria

## Indexed commentary on ARCHES so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=arches-nct02677896